Overview
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2020-01-10. Active
42 1020 1055 0000 9402 0463 0085- 80 1020 1055 0000 9702 0466 1361
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $299$299 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $185$185 | Prezes Zakładu Ubezpieczeń Społecznych |
Tenders
No recorded participation in tenders.
Trademarks
Alpha Pharmaceutical holds 4 active trademarks registered with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 2020.
| Mark | Protected until | |
|---|---|---|
| LYDEN(word) | Jun 4, 2030 | |
| SOLISTA(word) | Jun 4, 2030 | |
| SLANDIX(word) | Jun 4, 2030 | |
| Mark without a word element(figurative) | Feb 28, 2030 | |
| ALPHA PHARMACEUTICAL(word) | – |
Authorized Representatives
Manner of representation
If the management board is a one-person management board, the sole member of the management board is authorized to represent the company. If the management board is a multi-member management board, each member of the management board is authorized to represent the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Wołodymyr Hołubka (55) | 100 | $13,506.21 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Natur DayS.A. | $680,635.59 | naturday.pl | ||
| Biotriosp. z o.o. | $453,662.22 | biotrio.pl | ||
| Nature's Voicesp. z o.o. | $181,977.76 | naturesvoice.eu | ||
| Pexon Polandsp. z o.o. | $122,615.96 | pexon.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Bioresearch PharmaS.A. | $21,432.15 | bioresearchpharma.com | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Grupa FinepharmS.A. | – | finepharm.pl |
FAQ
Last updated: 2026-10-07